PharmaTimesOriginal article
Compass Pathways reports six‑month data confirming durable profile of COMP360
Phase 3positiveCOMP360Positive
AI Analysis
Summary
Compass Pathways reported six-month data from a Phase 3 trial of COMP360 demonstrating sustained benefit and a durable profile, supporting the company's forthcoming regulatory submission.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Six-month data confirming durable profile with sustained benefit in second Phase 3 trial
Importance:7/10
Sentiment:
0.75
Phase 3 datadurable efficacyregulatory submissionsustained benefit
Related Companies
Read the original article
Published by PharmaTimes on July 7, 2026 1:09 PM